Cyclosporine C0- versus C2-monitoring over three years in maintenance heart transplantation

Swiss Medical Weekly

Volumn 141, Issue FEBRUARY, 2011, Pages

  Hermann, Matthias ^a   Enseleit, Frank ^a   Fisler, Andrea E ^a   Flammer, Andreas ^a   Lüscher, Thomas F ^a   Noll, Georg ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Creatinine; Cyclosporine; Heart transplantation; Maintenance; Rejection

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; PREDNISONE; UREA; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; BLOOD PRESSURE; CALCIUM ANTAGONISM; CARDIAC GRAFT REJECTION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURETIC THERAPY; DRUG BLOOD LEVEL; DRUG MONITORING; FOLLOW UP; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; UREA BLOOD LEVEL; BIOPSY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; GRAFT REJECTION; MIDDLE AGED; PATIENT CARE; SWITZERLAND;

AGED; BIOPSY; CONTINUITY OF PATIENT CARE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SWITZERLAND;

EID: 79955796564     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13149     Document Type: Article

References (16)

1. Cheung A, Menkis AH. Cyclosporine heart transplantation. Transplant Proc. 1998;30(5):1881-4.
2. Levy G, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73(9 Suppl):S12-8.
3. Cantarovich M, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 1998;12(3):243-9. (Pubitemid 28269248)
4. Cantarovich M, et al. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplant Proc. 2004;36(2 Suppl):442S-447S.
5. Delgado DH, et al. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant. 2005;24(9):1343-6. (Pubitemid 41247820)
6. Solari SG, et al. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. Ther Drug Monit. 2005;27(4):417-21. (Pubitemid 41098814)
7. Wang P, et al. A monoclonal antibody fluorescent polarization immunoassay for cyclosporine. Transplant Proc. 1990;22(3):1186-8.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
9. Cunningham KS, Veinot JP, Butany J. An approach to endomyocardial biopsy interpretation. J Clin Pathol. 2006;59(2):121-9. (Pubitemid 43235574)
10. Stewart S, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-20.
11. Campbell SB, Johnson DW. Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice. Transplantation. 2003;75(11):1917-8. (Pubitemid 36734657)
12. Birsan T, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation. 2004;78(12):1787-91. (Pubitemid 40041646)
13. Iversen M, et al. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. J Heart Lung Transplant. 2009;28(9):919-26.
14. Mathias HC, et al. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant. 2005;24(12):2137-43. (Pubitemid 41814737)
15. Cantarovich M, et al. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 1999;68(12):1839-42. (Pubitemid 30027333)
16. Klingenberg R, et al. Allograft rejection of ISHLT grade >/=3A occurring late after heart transplantation - a distinct entity? J Heart Lung Transplant. 2003;2(9):1005-13.